[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-small-cell-lung-cancer-stage-i\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-small-cell-lung-cancer-stage-i":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643840","early-phase-1-nebulized-aer101-in-pre-op-nsclc-100643840",false,"NCT07631299","Nebulized AER101 in Pre-op NSCLC","Nebulized AER101 to Inhibit Glycolysis for Pre-Operative Non-small Cell Lung Cancer (NSCLC)","AER101","Inclusion Criteria:\n\n* 18 years or older\n* Agree to sign consent and follow study requirements\n* Recently diagnosed with lung adenocarcinoma or squamous cell carcinoma\n* Primary patients prior to resection\n* Candidate for surgery (patients are qualified for inclusion if surgery or radiation treatment are agreed to)\n* Baseline PET\u002FCT imaging performed at Stephenson Cancer Center available and performed within previous 30 days\n\nExclusion Criteria:\n\n* Recurrent tumor(s)\n* Nodal or metastatic tumor (multiple lung tumors are acceptable)\n* Pregnant patients\n* Patients unable to provide informed consent\n* Prisoners","ALL","18 Years","100 Years",{"count":21,"type":22},5,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","The primary objective of this pilot study is to determine if AER101 can decrease glycolysis in non-small cell lung cancer (NSCLC). Glycolysis is the process cells use to break down sugar (glucose) into a smaller substance in the fluid part inside the cell. Many lung cancers begin in bronchi, bronchioles and alveoli cells surrounding the airways, which enables nebulization to deposit AER101 on lung tumors.\n\nParticipants in the study will self-administer AER101 via a hand-held personal nebulizer three times per day (dosing at least 4 hours apart) for 14 days prior to undergoing surgery for lung cancer.",[28,29],"Non-small Cell Lung Cancer Stage I","Non-small Cell Lung Cancer Stage II",[31,32],"Non-small Cell Lung Cancer","Nebulization","NOT_YET_RECRUITING","2026-06-03",{"date":36,"type":37},"2026-06-08","ACTUAL",{"date":39,"type":22},"2026-06",{"date":41,"type":22},"2027-06",{"name":43,"class":44},"University of Oklahoma","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":65,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100617831","phase-2-a-study-of-bio-300-and-thoracic-radiation-therapy-in-people-with-non-small-cell-lung-cancer-and-interstitial-lung-disease-100617831","NCT07323732","A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease","A Phase II Study of BIO 300 to Reduce the Toxicity of Thoracic Radiotherapy for Patients With Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease (BREATHE)","Inclusion Criteria:\n\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. - Patient age ≥ 18 at time of consent\n* Stage I - II NSCLC (as per the American Joint Commission on Cancer (AJCC) 8th edition)\n\n  ° Pathologically proven diagnosis of cancer is strongly recommended but is not required if the risk of biopsy is unacceptable. If pathological evidence is not available, there must be clinical evidence for NSCLC and multidisciplinary consensus for treatment.\n* Interstitial Lung Disease diagnosis (one of the below)\n\n  * ILD as diagnosed and managed by a pulmonologist\n  * ILD based on diagnostic imaging criteria and abnormal DLCO\n  * ILD as a result of connective tissue diseases (e.g., polymyositis\u002Fdermatomyositis, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, mixed connective tissue disease)\n* ECOG performance status of 0 - 3\n* Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Women \\\u003C50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women ≥50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).\n* Life expectancy of at least 6 months\n\nExclusion Criteria:\n\n* Previous thoracic radiation\n* History of pneumonectomy\n* Major surgical procedure (e.g. intra-cranial, intra-thoracic, intra-abdominal, or intra-pelvic) within 28 days prior to enrollment.\n* Severe concurrent illness that may preclude timely completion of thoracic radiation or study procedures\n* Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.\n* ILD exacerbation requiring hospitalization in the last 30 days\n* Poorly controlled cardiac arrhythmias not responding to medical therapy or a pacemaker\n* Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential unless they are willing to employ a highly effective non-estrogen based contraception from screening to 30 days after the last dose of BIO 300 or to abstain from sexual intercourse during these time periods.\n\n  1. Effective method of non-estrogen-based contraception: condom and a diaphragm, condom and intrauterine device, condom and Depo-Provera, condom and Nexplanon, or condom and progesterone mini-pill\n  2. Women who have been off estrogen contraceptives for a minimum 5 days prior to the first scheduled day of study intervention dosing are eligible.\n* Concomitant medications:\n\n  1. Any investigational anticancer therapy.\n  2. Planned concurrent chemotherapy or immunotherapy\n  3. Biologic drugs targeting the immune system (e.g. TNFα blockers, anakinra, rituximab, abatacept, tocilizumab) planned to be use concurrently with BIO 300",{"count":54,"type":22},25,[56],"PHASE2","The purpose of this study to find out whether giving BIO 300 in combination with thoracic radiation therapy is effective in preventing pneumonitis in people with non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD).",[59,60,61,62,28,29,63,64],"NSCLC","NSCLC, Stage I","NSCLC Stage II","Non Small Cell Lung Cancer","Interstitial Lung Disease","Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)",[62,66,67,59,68,61,63,64,69,70],"Non Small Cell Lung Cancer Stage I","Non Small Cell Lung Cancer Stage II","NSCLC Stage I","Memorial Sloan Kettering Cancer Center","25-310","RECRUITING","2026-03-02",{"date":74,"type":37},"2026-03-03",{"date":76,"type":37},"2026-01-06",{"date":78,"type":22},"2029-01-06",{"name":69,"class":44},7,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":90,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100256852","clinical-research-platform-into-molecular-testing-treatment-and-outcome-of-non-small-cell-lung-carcinoma-patients-100256852","NCT02622581","Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients","CRISP","Inclusion Criteria:\n\nPatients who meet all of the following criteria are eligible for the project:\n\n* Age ≥ 18 years\n* Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments\n\nMain project (Metatstatic NSCLC):\n\n* Confirmed non-small cell lung cancer (NSCLC)\n* Informed consent no later than four weeks after start of first-line systemic treatment or no later than four weeks after diagnosis for patients receiving \"best supportive care only\"\n* Stage IV, or stage IIIB\u002FC (UICC8) if patient is ineligible for curative surgery and\u002For radiochemotherapy\n* Systemic therapy or best supportive care\n\nSatellite Stage I\u002FII\u002FIII (NSCLC):\n\n* Confirmed non-small cell lung cancer (NSCLC)\n* Informed consent no later than four weeks after start of first anti-tumor treatment (including surgery and radiotherapy) or no later than four weeks after diagnosis for patients receiving \"best supportive care only\" (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy)\n* Stage I, Stage II, stage IIIA, or stage IIIB\u002FC (UICC8)\n* Systemic (chemo)therapy and\u002For radiation therapy and\u002For surgery or best supportive care\n\nSatellite SCLC\n\n* Confirmed Small cell lung cancer (SCLC)\n* Informed consent no later than four weeks after start of first anti-tumor treatment or no later than four weeks after diagnosis for patients receiving \"best supportive care only\" (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy)\n* Systemic (chemo)therapy and\u002For radiation therapy and\u002For surgery or best supportive care\n\nExclusion Criteria:\n\nnone",{"count":89,"type":22},12400,"3 Years","OBSERVATIONAL","Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany",[94,95,29,96,97,28],"Metastatic Non-small Cell Lung Cancer (NSCLC)","Non-small Cell Lung Cancer Metastatic","Non Small Cell Lung Cancer Stage III","Small-cell Lung Cancer","2025-02-14",{"date":100,"type":37},"2025-02-18",{"date":102,"type":37},"2015-12",{"date":104,"type":22},"2027-12",{"name":106,"class":44},"AIO-Studien-gGmbH",1]